Domestic approval of EU-approved Novavax is imminent

By Lee, Tak-Sun | translator Choi HeeYoung

21.12.22 06:00:38

가나다라 0

The MFDS recently set up major test items for lot release

If the permit policy is followed within 40 days, the end of this month will be possible

The quarantine authorities will carry forward 40 million domestic supplies next year

As the European Union (EU) approved the conditional sale of the NovaVax COVID-19 vaccine, attention is being paid to when it will be approved in Korea. As the MFDS is known to be preparing for Novavax's approval for national lot release, analysts say that approval is imminent in Korea.

On the 20th, the European Commission (EMA) approved the conditional sale of the COVID-19 vaccine developed by Novavax. A few hours ago, the European Medicines Agency (EMA) recommended conditional sales approval. The EMA recommended approval for the use of the vaccine to prevent COVID-19 over the age of 18. Novavax was found to have a preventive effect of 90% in clinical trials of about 45,000 people in the United States,

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)